Outreach and Connection to Care for Chronic Kidney Disease in a Workplace Wellness Setting: A Cost-Effectiveness Analysis

被引:0
|
作者
Li, Yonghong [1 ]
Devlin, James J. [1 ]
机构
[1] Quest Diagnost, 33608 Ortega Highway, San Juan Capistrano, CA 92675 USA
关键词
chronic kidney disease; cost-effectiveness analysis; Markov modeling; CARDIOVASCULAR OUTCOMES; NEPHROPATHY; INHIBITORS;
D O I
10.1089/pop.2019.0206
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Because chronic kidney disease (CKD) is underdiagnosed, many patients do not receive care that could slow or prevent progression. Potential CKD patients can be identified during employee wellness events and referred into care by a CKD outreach program. This study assessed the health and economic benefits associated with a CKD outreach program. A model-based cost-effectiveness analysis was conducted for a cohort of patients at risk for CKD under 2 scenarios: wellness events with a CKD outreach program and wellness events without outreach. The outreach program identified potential CKD patients based on estimated glomerular filtration rates. Health outcomes and total cost to payers were estimated with Markov models using 1-year cycles. Because outreach could be offered to either patients with diabetes or to all potential CKD patients, these groups were modeled separately. The authors assumed 40% percent of potential CKD patients accepted the invitation to participate in the CKD outreach program. Model parameters were taken from peer-reviewed literature. The study was conducted from the perspective of self-insured employers over a 5-year time horizon. The study found that the CKD outreach program resulted in a gain of 2.3 quality-adjusted life-years and saved $500,211 when 1000 potential CKD patients with diabetes were invited. When potential CKD patients were invited without regard for diabetes status, 0.8 quality-adjusted life-years were gained at a cost savings of $34,161. The authors concluded that CKD outreach programs can improve health outcomes for patients with CKD and save costs for payers.
引用
收藏
页码:487 / 494
页数:8
相关论文
共 50 条
  • [41] Setting priorities for the health care sector in Zimbabwe using cost-effectiveness analysis and estimates of the burden of disease
    Hansen K.S.
    Chapman G.
    Cost Effectiveness and Resource Allocation, 6 (1)
  • [42] COST-EFFECTIVENESS ANALYSIS OF IVABRADINE IN CHRONIC STABLE ANGINA PATIENTS IN A FINNISH SETTING
    Felix, J.
    Almeida, J.
    Joutseno, J.
    Alegre, P.
    VALUE IN HEALTH, 2009, 12 (07) : A330 - A330
  • [43] Cost-Effectiveness Analysis of Integrated Care in Management of Advanced Chronic Obstructive Pulmonary Disease (COPD)
    Bandurska, Ewa
    Damps-Konstanska, Iwona
    Popowski, Piotr
    Jedrzejczyk, Tadeusz
    Janowiak, Piotr
    Swietnicka, Katarzyna
    Zarzeczna-Baran, Marzena
    Jassem, Ewa
    MEDICAL SCIENCE MONITOR, 2019, 25 : 2879 - 2885
  • [44] Cost-effectiveness of sevelamer in the treatment of hyperphosphatemia associated with chronic kidney disease in Mexico
    Idrovo, J.
    Rivas, R.
    Zapata, L.
    VALUE IN HEALTH, 2008, 11 (03) : A301 - A301
  • [45] Cost-effectiveness of hemofiltration to prevent contrast nephropathy in patients with chronic kidney disease
    Klarenbach, SW
    Pannu, N
    Tonelli, MA
    Manns, BJ
    CRITICAL CARE MEDICINE, 2006, 34 (04) : 1044 - 1051
  • [46] THE COST-EFFECTIVENESS OF PHOSPHATE BINDERS FOR THE TREATMENT OF HYPERPHOSPHATEMIA IN CHRONIC KIDNEY DISEASE (CKD)
    Keith, M. S.
    Carlton, R.
    Meissner, B. L.
    VALUE IN HEALTH, 2009, 12 (07) : A309 - A309
  • [47] Cost-effectiveness of screening for chronic kidney disease: existing evidence and knowledge gaps
    van Mil, Dominique
    Pouwels, Xavier G. L., V
    Heerspink, Hiddo J. L.
    Gansevoort, Ron T.
    CLINICAL KIDNEY JOURNAL, 2024, 17 (01)
  • [48] COST-EFFECTIVENESS OF SEVELAMER IN THE TREATMENT OF HYPERPHOSPHATEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE IN ARGENTINA
    Rivas, R.
    Idrovo, J.
    Zapata, L.
    VALUE IN HEALTH, 2010, 13 (03) : A210 - A210
  • [49] Stochastic cost-effectiveness analysis of chronic venous leg ulcers -: The case of Promogran® in a Swedish health care setting
    Ghatnekar, O
    Hjelmgren, J
    Ödegaard, K
    Bjellerup, M
    VALUE IN HEALTH, 2002, 5 (06) : 456 - 457
  • [50] Cost-effectiveness of Finerenone in Addition to Standard of Care for Patients with Chronic Kidney Disease and Type 2 Diabetes in China
    Ming, Jian
    Hong, Guanqi
    Xu, Yingrui
    Mernagh, Paul
    Pochopien, Michal
    Li, Hongchao
    ADVANCES IN THERAPY, 2024, 41 (08) : 3138 - 3158